Pedro Henrique Teixeira Carneiro

Pedro Henrique Teixeira Carneiro

Auto-generated profile, based on publicly available information

Pedro Henrique Teixeira Carneiro

Departamento de Medicina, Universidade de Santo Amaro, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2025 in Clinical Neuropharmacology
Verified
Journal Article
Closed access
MCMurilo Marmori Cruccioli
Murilo Marmori Cruccioli
PCPedro Henrique Teixeira Carneiro
Pedro Henrique Teixeira Carneiro
JPJorge Ferreira Jasmineiro Pitanga
Jorge Ferreira Jasmineiro Pitanga
CFCamila Carneiro Ferreira
Camila Carneiro Ferreira
RLRegina Carneiro Leão
Regina Carneiro Leão
FSFilipe P. Sarmento
Filipe P. Sarmento
Background: While there is still debate over the benefit of antipsychotics in delirium management, surveys indicate their frequent use in clinical practice. Previous systematic reviews and meta-analyses have focused on assessing the effectiveness of antipsychotics versus placebo in delirium management. However, despite increasing access to atypical antipsychotics in hospital settings, robust analyses of studies comparing the effectiveness of haloperidol and atypical antipsychotics are lacking. Objectives: To conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing the effectiveness and safety of haloperidol versus atypical antipsychotics in the management of delirium patients. Methods: We conducted a systematic search of Medline, Scopus, and Cochrane for RCTs comparing atypical antipsychotics with haloperidol in delirium patients. Odds ratio (OR) was used to analyze dichotomous variables. Continuous outcomes were compared using mean difference (MD) and standardized mean difference (SMD). The random effects model was applied to all endpoints. Results: Eleven RCTs (n=1450 patients) met the eligibility criteria. Delirium severity (SMD, −0.03; [95% CI, −0.20 to 0.15]; P = 0.78) and overall mortality (OR, 1.26; [95% CI, 0.88-1.80]; P = 0.20) did not differ significantly between groups. However, patients treated with haloperidol had significantly higher odds of experiencing extrapyramidal symptoms compared with those treated with atypical antipsychotics (OR, 2.72; [95% CI, 1.26-5.87]; P = 0.01). Conclusions: While there were no significant differences in the effectiveness between treatments, patients treated with haloperidol had nearly a 3-fold increase in the incidence of extrapyramidal symptoms, indicating a potential advantage of atypical antipsychotics in minimizing adverse effects.

1 February 2026 in Neurology Clinical Practice
Verified
Journal Article
Closed access
JPJorge Resende Gondim Jasmineiro Pitanga
Jorge Resende Gondim Jasmineiro Pitanga
MCMurilo Marmori Cruccioli
Murilo Marmori Cruccioli
PCPedro Henrique Teixeira Carneiro
Pedro Henrique Teixeira Carneiro
YFYasmin Bastos Faller
Yasmin Bastos Faller
LSLetícia Torres da Silva
Letícia Torres da Silva
FSFilipe P. Sarmento
Filipe P. Sarmento
Neurocysticercosis is the most common parasitic infection of the CNS and remains a significant, yet often neglected, public health issue in endemic regions. High-quality evidence suggests that albendazole monotherapy leads to superior clinical outcomes compared with placebo or praziquantel. However, there is still insufficient evidence regarding the efficacy and safety of combined albendazole-praziquantel therapy. This systematic review and meta-analysis aims to compare combined antiparasitic therapy with albendazole and praziquantel with albendazole monotherapy, evaluating whether dual therapy offers superior therapeutic benefits in the management of neurocysticercosis while maintaining an acceptable safety profile. We searched MEDLINE, Embase, and the Cochrane Library for randomized controlled trials (RCTs) published until April 2024 that compared combined albendazole-praziquantel therapy with albendazole monotherapy for the treatment of neurocysticercosis. Statistical analysis was performed using Review Manager 5.4.1, with odds ratios (ORs) and 95% confidence intervals (CIs) reported. A random-effects model was applied to all end points. The risk of bias was assessed for each study, and the certainty of evidence was evaluated using the GRADE approach. Five RCTs were included, comprising a total of 320 patients, 49% of whom received combined therapy. Complete cyst resolution was significantly more frequent in patients treated with combined albendazole-praziquantel therapy compared with albendazole monotherapy (OR = 3.06; 95% CI [1.81-5.19]; p = 0.0001; I 2 = 5%; high-certainty evidence). In a subgroup analysis restricted to patients with 1-2 cysts (248 patients), no statistically significant difference in complete cyst resolution was observed (OR = 1.98; 95% CI [0.92-4.27]; p = 0.08; I 2 = 34%; very-low-certainty evidence). There was no significant difference in seizure recurrence between treatment strategies (OR = 1.28, 95% CI [0.56-2.91], p = 0.55, I 2 = 0%; moderate-certainty evidence). Similarly, the incidence of adverse effects did not differ significantly between groups (OR = 1.40, 95% CI [0.72-2.72], p = 0.30, I 2 = 0%; moderate-certainty evidence). This systematic review and meta-analysis demonstrated a threefold increase in complete cyst resolution among patients receiving combined therapy, suggesting its superiority over albendazole monotherapy for the management of neurocysticercosis. In addition, no significant differences were observed between treatment strategies regarding seizure or adverse events.

25 December 2025 in Neurodegenerative Disease Management
Verified
Journal Article
Closed access
MCMurilo Marmori Cruccioli
Murilo Marmori Cruccioli
PCPedro Henrique Teixeira Carneiro
Pedro Henrique Teixeira Carneiro
JPJorge Ferreira Jasmineiro Pitanga
Jorge Ferreira Jasmineiro Pitanga
YRYohanna Rossi
Yohanna Rossi
LSLeticia Torres da Silva
Leticia Torres da Silva
FSFilipe P. Sarmento
Filipe P. Sarmento
Fatigue affects up to 95% of individuals with multiple sclerosis (MS), significantly impairing daily functioning. Management is multidisciplinary, and although amantadine lacks U.S. FDA approval for this indication, it remains the most commonly prescribed pharmacologic option despite inconsistent supporting evidence. This systematic review and meta-analysis evaluated the effectiveness of amantadine for MS-related fatigue. We searched MEDLINE, EMBASE, and Web of Science for randomized controlled trials (RCTs) comparing amantadine to placebo in the treatment of MS-related fatigue. Statistical analyses were conducted using R. Standardized mean differences (SMDs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess fatigue severity and adverse effects incidence, respectively. A random-effects model was applied to all analyses. A total of nine RCTs were included, involving 601 patients, 66% of whom received amantadine. Amantadine use was not associated with a significant reduction in fatigue severity compared to placebo (SMD -0.22; [95% CI -0.72; 0.27]; p = 0.37). However, it was associated with higher odds of insomnia (OR = 2.33; [95% CI 1.27; 4.29]; p = 0.006). This meta-analysis suggests that amantadine is not effective for treating MS-related fatigue and is associated with an increased risk of adverse effects, particularly insomnia. These results cast doubt on its continued first-line use.

1 April 2026 in Neurology Clinical Practice
Verified
Journal Article
Closed access
JPJorge Resende Gondim Jasmineiro Pitanga
Jorge Resende Gondim Jasmineiro Pitanga
MCMurilo Marmori Cruccioli
Murilo Marmori Cruccioli
PCPedro Henrique Teixeira Carneiro
Pedro Henrique Teixeira Carneiro
YFYasmin Bastos Faller
Yasmin Bastos Faller
LSLetícia Torres da Silva
Letícia Torres da Silva
FSFilipe P. Sarmento
Filipe P. Sarmento